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Abstract 
Robustness, understood as the maintenance of specific functionalities of a given system 
against internal and external perturbations, is pervasive in today’s biology. Yet precise 
applications of this notion to the immune system have been scarce. Here we show that the 
concept of robustness sheds light on tissue repair, and particularly on the crucial role the 
immune system plays in this process. We describe the specific mechanisms, including 
plasticity and redundancy, by which robustness is achieved in the tissue reconstruction 
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system (TRS). In turn, tissue repair offers a very important test case for assessing the 
usefulness of the concept of robustness, and identifying different varieties of robustness.   
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Introduction 
 
Robustness can be defined as the maintenance of specific functionalities of a given system 
against internal and external perturbations [1,2]. The term, routinely used in engineering 
(e.g. [3]), is now pervasive in the life sciences [4]. Systems and processes as diverse as 
bacterial chemotaxis, biochemical networks, cells, organisms, and ecosystems, among many 
others, have been described as robust [5–9]. For example, a plane is robust when it 
continues to fly despite severe turbulence (for example thanks to the flexibility of its wings), 
and a bacterial cell is robust to modifications in genetic regulation when it tolerates a high 
number of these modifications [10]. 
The notion of robustness, however, is very broad, and often elusive. To make it more 
precise, it has long been emphasized (e.g., [11]) that two crucial questions must 
systematically be addressed when talking about robustness: first, what is robust, and second 
to what is it robust? In other words, a system is not robust in general; rather, it is robust to a 
certain kind of perturbations that can occur at a given level (or at a limited number of 
levels). The most stirring applications of the concept of robustness are those where talking 
about robustness seems directly operative, that is, sheds a new and important light on a 
given phenomenon, as illustrated by several cases including bacterial chemotaxis [7].  
The aim of the present paper is to ask whether the concept of robustness can 
illuminate the processes of tissue repair and tissue regeneration, and whether, in turn, tissue 
repair and tissue regeneration offer a promising basis to better define the notion of 
robustness applied to biological phenomena. We are therefore interested in robustness at a 
particular level, namely that of tissues, and against a particular set of perturbations, namely 
damages made on tissues (physical or chemical aggressions, infectious agents, or “internal” 
 4 
stresses). Our focus on repair and regeneration at the tissue level is justified by the recent 
wealth of data on this issue [12], and by the obvious clinical interest of this topic, especially 
in the age of regenerative medicine [13], but it is important to keep in mind that repair 
occurs also at other levels (including genetic [14] and cellular [15] level) in the organism. The 
idea that repairing oneself is fundamental to the organism’s unity and individuality has been 
suggested at least since the 19th century, particularly by physiologist Claude Bernard [16]. 
More recently, the concept of robustness has been commonly associated with repair and 
regeneration [17–20]. Much remains to be said, however, about how robustness and tissue 
repair can shed light one on the other. 
Tissue repair and regeneration involve a horde of components and pathways, 
including structural (e.g., fibroblasts, ECM, etc.) and immunological (e.g., neutrophils, 
macrophages, etc.) ones [12,20–22]. For this reason, we propose the concept of the “tissue 
reconstruction system” (TRS) to embrace all the different aspects of this phenomenon (see 
Figure 1). Repair is essential for the survival and maintenance of the body [16,21]. Failures in 
the repair process can lead to various pathological conditions, including fibrotic diseases, 
ulcers, hypertrophic and keloid scars, as well as cancers [23–25]. Repair is continuously 
occurring, to some degree, in organisms (e.g., skin renewal), in response to their constant 
exposure to damages of different types (physical, chemical, radiological, etc.). Even though 
there exists to a large extent a continuum between repair and regeneration [26], the two 
phenomena can be considered distinct in several respects. Regeneration describes the 
capacity to regrow complex organs entirely, generally with the implication of several cell 
types [18,27–29]. In mammals, for example, the renewal of the epidermis is a form of repair, 
because it involves a single cell type (keratinocytes), whereas for the liver one can talk about 
regeneration as it involves several cell types (hepatocytes, sinusoidal endothelial cells, 
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stellate cells, Kupffer cells, etc.) [30]. Many repair mechanisms have been conserved across 
different taxa, including Drosophila, zebrafish, chick, and mammals [22,26]. The capacity to 
regenerate many complex organs such as limbs, however, is found only in a subset of living 
things [26,27]. One important aim of this paper is to better clarify the similarities and 
differences between repair and regeneration, thanks to the concept of robustness. 
We explain here how robustness can help better characterize the process of tissue 
reconstruction, through a description of the specific mechanisms, including plasticity and 
redundancy, by which robustness is achieved in the TRS. We also demonstrate that different 
repair-associated disorders (such as fibrosis, ulcers, and cancers) can be understood as the 
result of deregulated robustness. In turn, we show that the TRS offers a remarkable test case 
to defining the notion of robustness in a more precise and operational way, and more 
specifically to distinguishing different forms of robustness (structural vs. functional; 
preventive vs. corrective; partial vs. complete; dysfunctional vs. as a dysfunction).  
 
1. What is robustness? 
 
With the increasing attention paid recently to systems biology and complex systems, many 
living processes or systems have been described as “robust” [1,2,31]. The exact meaning of 
the word “robustness” often remains, however, elusive. The term originated in physics [11], 
and engineering [32] (though the engineering-related meaning is itself rooted in the 
physiology of the 19th and 20th century, including the work of Claude Bernard [33]). (On the 
relationship between biology and engineering, see [34]). In general, robustness is defined as 
the maintenance of specific functionalities of the system against internal and external 
perturbations. Two major requirements for any claim about biological robustness are to 
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determine what exactly the robust system is, and against which type(s) of perturbations it is 
said to be robust. Importantly, robustness does not amount to conservation or absence of 
change. Robustness allows changes in the structure and components of the system owing to 
perturbations, but the key idea is that robustness leads to the maintenance of specific 
functions. It is likely that robustness is an evolved trait [9,35,36]. Moreover, there are often 
trade-offs between robustness and other traits. In particular, systems that are evolved to be 
robust against certain perturbations can be extremely fragile to unexpected perturbations 
(see, e.g., [2,4]). 
Despite the fact that, historically, the concept of robustness took root to some extent in 
the concept of homeostasis, the two notions are different. Homeostasis is about maintaining 
constant (or almost constant, within a certain range) a value (e.g., body temperature in 
homeothermic animals) [37,38]. Robustness, in contrast, is about maintaining a given 
function F against given types of perturbations (P1, P2, etc.). 
Examples of robust processes or systems in biology abound [4]. These include 
chemotaxis in bacteria [6,7], cell cycle in budding yeast [39], reliable development despite 
noise and environmental variations [40], ecosystem reconstruction after a catastrophic 
event [8], among many others. 
As shown by Kitano [2], the four main mechanisms that ensure robustness are: system 
control, alternative mechanisms, modularity, and decoupling. System control consists in 
negative and positive feedbacks that enable the system to reach robustness against some 
perturbations. An example is bacterial chemotaxis, in which negative feedback plays a major 
role [41]. Robustness can also be realized by alternative (or “fail-safe”) mechanisms, that is, 
multiple routes to achieve a given function, which is to say that the failure of one of these 
routes can be compensated by another. This includes redundancy (where identical or nearly 
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identical components can realize a given function) and diversity (where heterogeneous 
components can realize a given function). There are now many examples of these 
phenomena in the immune system (e.g., [42]). Modularity is another important dimension of 
robustness: robustness is often achieved by modules, that is, flexible sets of components 
that collectively realize a given function, rather than by individual components [43]. Finally, 
decoupling is the prevention of undesired connection between low-level variations and high-
level functionalities. An example is the buffer mechanisms that decouple genetic variations 
from phenotypic expression, e.g., HSP chaperones [44]. 
 Here we focus on how the concept of robustness can be applied to the immune 
system and the TRS across the living world. Robustness has not been widely mentioned in 
immunology, though some exceptions exist (e.g., [33,45–47]). In particular, Mantovani [47] 
proposed that robustness provides a conceptual framework to understand intriguing aspects 
of the chemokine system, most prominently its redundancy (see also Mantovani, this special 
issue). Germain, Altan-Bonnet, and colleagues have explored theoretically and 
experimentally the mechanisms through which T cells can be both robust and adaptable to 
variations in protein expression [45]. Kourilsky has proposed to understand the immune 
system as conferring robustness to the whole organism via its capacity to systematically 
detect and respond to internal as well as external perturbations [33]. The question raised 
here is different and complementary, in so far as robustness is examined at the tissue level, 
and we ask which exact roles the immune system plays in this tissue-level robustness. 
In what follows, we detail how the TRS works, mainly via five processes, namely 
plasticity, functional redundancy, constant surveillance, restraint, and dynamic adjustment. 
We then show how pathologies associated with dysfunctions in tissue repair (e.g, fibrosis, 
ulcers, and cancer) can be understood as resulting from a deregulation of one or several of 
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these five processes. We propose that the TRS offers a remarkable test case to define the 
notion robustness in a more precise and operational way, and more specifically to 
distinguishing different forms of robustness (structural vs. functional; preventive vs. 
corrective; partial vs. complete; dysfunctional vs. as a dysfunction). Importantly, we will 
consider both “repair” (defined as the partial reconstruction of an organ or tissue) and 
“regeneration” (defined as the complete reconstruction of a complex organ or tissue) 
examples, and explain how the concept of robustness helps clarify the differences between 
repair and regeneration. 
 
 
2. The mechanisms that mediate tissue reconstruction 
 
Tissue reconstruction is a complex and dynamic process, comprising overlapping, highly 
orchestrated stages – namely inflammation, tissue formation, and tissue remodeling [21]. 
Tissue reconstruction involves many molecular and cellular components, which tightly 
interact. Understanding the interactions between these components and how they are 
regulated both spatially and temporally is a major aim for anyone interested in tissue repair, 
regeneration, and repair-associated pathologies. We show here that the TRS exhibits five key 
features that participate in robustness, and which are shared by many actors involved in the 
TRS: the TRS is plastic, redundant, under constant surveillance, restrained, and continuously 
dynamic. 
 
2.1. Plasticity in the TRS 
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First, a major feature of the TRS is the plasticity of the cells involved in tissue reconstruction. 
The word “plasticity” is used with different and sometimes confusing meanings in the 
scientific literature. Here we understand cell plasticity in two different and important senses 
[20]. The first sense is intra-lineage cell plasticity, that is, changes in cell function and 
phenotype within a given cell lineage – for example, M1 macrophages turning into M2 
macrophages. This is sometimes called “functional plasticity” [48]. The second sense is trans-
lineage cell plasticity, that is, the switch from one lineage to another – e.g., from 
macrophages to fibroblasts [49]. This can also be called plasticity by “transdifferentiation” 
[50] or by “reprogramming” – a phenomenon now known to occur in some non-immune 
cells [51]. Actors of plasticity in tissue reconstruction are diverse, from immune to non-
immune cells. In what follows, we describe the main cellular actors in the repair process, 
with a particular emphasis on how they illustrate the phenomenon of plasticity. We show 
that this plasticity is central to the functioning of the TRS.  
Far from being “one-shot” weapons, long-living neutrophils – which are central 
players in tissue reconstruction – are remarkably plastic. Indeed, neutrophils can 
differentially switch phenotypes, and display distinct subpopulations under different 
microenvironments [52]. At the inflammatory stage of the repair process, neutrophils can 
play either a pro-resolving or an anti-resolving role. In addition to this intra-lineage plasticity, 
repair-associated neutrophils are capable of trans-lineage plasticity (plasticity by 
transdifferentiation) [53–56]. 
Type 1 macrophages (M1) drive the early inflammatory responses that lead to tissue 
destruction, whereas type 2 macrophages (“M2” or “alternatively activated reparative 
macrophages”) exert a central role in wound healing [57–62]. Generation of a pro-type 2 
microenvironment gradually leads to the switch from inflammatory to pro-repair 
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macrophages. These cells promote tissue repair by producing pro-reparative cytokines and 
participate in a pro-type 2 microenvironment. A wide range of macrophage subtypes exists 
[50,58,63,64]. Efficient tissue repair requires inflammatory macrophages, tissue repair 
macrophages, and resolving macrophages (producers of resolvins, IL-10 and TGF-b) 
[50,60,65]. Beyond intra-lineage plasticity, macrophages might participate actively in the 
tissue-remodeling phase of repair process by transdifferentiation into other cell types, 
notably endothelial cells [66].  
Innate Lymphoid Cells (ILCs) are a recently discovered family of immune cells that 
includes three subsets: ILC1, ILC2 and ILC3 [67–69]. ILC2-secreted amphiregulin, a protein 
shown to orchestrate tissue repair [70], promotes wound healing by acting directly on 
fibroblasts, leading to ECM deposit. ILC responses to different stimuli allow intra-lineage 
plasticity between the different subsets [71,72]. This plasticity between different ILC 
subtypes might allow for rapid innate immune responsiveness in repair [73,74]. 
Overall, cell plasticity is a pivotal process by which tissue reconstruction is achieved. 
This is confirmed by the fact that, as detailed below, inappropriate realizations of cellular 
plasticity (excess or insufficiency) may lead to various disorders. 
 
2.2. Functional redundancy in the TRS 
 
Functional redundancy is another important feature of the TRS. Functional redundancy 
describes a situation in which different elements have similar functions or similar effects on 
a trait [4]. Though some forms of functional redundancy occur in every organism as part of 
normal functioning, this phenomenon has often been observed in pathological contexts, 
where it appears that an organism deficient in one cell type can “compensate” this 
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deficiency thanks to other cell types or other molecules or pathways [75]. The TRS often 
displays “degeneracy”, which refers to the existence of structurally diverse but functionally 
similar components [75]. Overall, the TRS is characterized by a high level of redundancy, 
even though some components and pathways seem to be pivotal in the reconstruction 
process. 
ILCs have potent immunological functions in experimental conditions, but their 
contributions to immunity in natural conditions are unclear. It has been shown that SCID 
patients with IL2RG and JAK3 mutations and ILC-deficient had no particular susceptibility to 
disease [42]. Thus, ILCs appear to be dispensable in humans who have a functional adaptive 
immune system, at least in the context of modern medicine and hygiene conditions [42,76].  
Functional redundancy allows the evocation of an overall type 1 or 2 immune 
response rather than talking more restrictively about type 1 or 2 neutrophils/macrophages/T 
cells. Those cells often produce the same types of molecules (albeit sometimes with 
different temporal patterns). This redundancy is not only important to maintain robustness 
against perturbations; it also creates feedback loops (and thereby a virtuous or vicious circle, 
depending on the situation), participating in the establishment of a local microenvironment 
that displays particular features.  
Besides immunological redundancy, immune cells participate in the secretion of 
structural molecules such as matrix metalloproteinases (MMP) altogether with fibroblasts, 
pericytes, and endothelial cells. The relative importance of macrophage and other immune 
cell contribution to tissue reconstruction compared to the aforementioned structural cells 
might depend on the nature of the tissue and the injury. 
 
2.3. Constant surveillance 
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Tissue reconstruction is an active process where some actors are on constant standby. It is of 
major importance at the level of DNA repair, as DNA lesions occurring during reprogramming 
are monitored by a surveillance mechanism called the zygotic checkpoint [77]. At the tissue 
level, some cells, including various types of immune cells [78], are highly specialized in the 
surveillance of damages. Of crucial importance are tissue-resident sentinel cells, as they are 
present and on standby before any damages. 
ILCs are found preferentially on epithelial barrier surfaces such as the skin, lungs, and 
gut, where they protect against infection and maintain the integrity of the barriers. ILCs are 
tissue-resident sentinels enriched at mucosal surfaces. They exert a constant surveillance on 
epithelia, and have a complex crosstalk with their microenvironment. They are highly 
involved in tissue repair through their sentinel position and the cytokines they produce 
[79,80].  
Different tissues often have their preferential sentinels, such as NK cells in the liver, 
or Langerhans cells in the skin. Cells of the innate but also adaptive immune system are 
involved in this surveillance. In particular, tissue resident memory T cells (TRM) – which reside 
in tissues without recirculating through the blood or lymph, and constitute a 
transcriptionally and phenotypically unique T cell lineage – have been shown to be key 
guardians against viral infections [81].   
Cells traditionally seen as non-immune such as epithelial cells (ECs) play an important 
role in this collaborative surveillance process. They line body surface tissues and provide a 
physicochemical barrier to the external environment. This barrier is not a mere passive 
mechanical protection. Frequent microbial and non-microbial challenges cause activation of 
ECs, with release of cytokines and chemokines as well as alterations in the expression of cell-
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surface ligands. Epithelial stress is rapidly sensed by tissue-resident immune cells, which can 
directly interact with self-moieties on ECs and initiate both local and systemic immune 
responses. ECs are thus key drivers of immune surveillance at body surface tissues [82]. 
 
2.4. Restraint of the TRS 
 
Detecting and responding to damages is so central for the organism’s survival that the TRS is 
always on alert, ready to be triggered. But at the same time this system also constitutes a 
potential threat for the organism (inflammation, tissue formation, and tissue remodeling can 
all go awry, with potentially dramatic consequences), and must therefore be constantly kept 
under control. Numerous cells restrain the TRS through negative feedback, active production 
of pro-resolving molecules, and other dynamic mechanisms. These cells are important at all 
stages but they are particularly crucial for the pro-resolving phase after inflammation. 
Pro-resolving neutrophils demonstrate the ability to: (i) produce several pro-resolving 
mediators (as lipoxins), (ii) form NETs and aggregated NETs, according to a cell-density 
dependent sensing mechanism, which dismantles the pro-inflammatory gradient by 
degrading the inflammatory cytokines and chemokines, (iii) store and release the pro-
resolving protein annexin A1 [83].  
Inflammation resolution is partly mediated by the clearance of apoptotic neutrophils 
by macrophages through efferocytosis [84]. Non-apoptotic neutrophils can leave the injury 
site by reverse transmigration. Recently described resolving macrophages (producers of 
resolvins, IL-10 and TGF-b) are important actors of repair regulation.   
In mice, some regulatory T cells (Tregs) are able to produce amphiregulin, favoring 
the resolving phase of the inflammation process [85]. Depletion of muscle Tregs has 
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profound impact on muscle regeneration with loss of regenerative fibers, collagen 
deposition and fibrosis, leading to a disorganized tissue structure. In the absence of Tregs, 
effector T cell infiltrate increases in the injured muscle and the switch from inflammatory to 
anti-inflammatory macrophage diminishes.  
 
2.5. Dynamic adjustment of the TRS 
 
TRS is a highly dynamic process implying a large recruitment of various cells, with 
movements in a tri-dimensional matrix, and with many back and forth between different 
steps that are not fixed and can often overlap. The dynamic character of the TRS is visible at 
the level of the recruited cells, but also of the resident cells.  
Standby periods are not to be considered totally at rest. Resident cells are never 
completely motionless. Moreover, cells are constantly replaced in a dynamic process. 
Tissues are continuously exposed to potentially hazardous environmental challenges in the 
form of inert material and microbes. In the epidermis, for example, Langerhans cells (LC) 
form a dense network of cells capable of capturing antigens and migrating to the lymph 
node after crossing the basement membrane into the dermis, and they are able to promote 
tolerance or immune responses [86]. Velocity of migration is partly regulated by the 
microenvironment, and skin Tregs display a much slower migration compared to effector 
CD4+ T cells, although acute inflammation results in a rapid increase in their motility [87]. 
Gradients of chemokines largely participate in cell recruitment when damages occur. 
CD14+ monocytes and neutrophils are very mobile cells, highly and promptly recruited in 
case of injury [88]. The recruitment of neutrophils during the inflammatory phase is linked to 
a sharply regulated communication system based on the CXC chemokine/CXC receptors 
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balance [89]. The injury triggers the production of G-CSF that converts the CXCR4 dominant 
signaling to that of CXCR2 in the bone marrow microenvironment, leading to the release of 
more mature neutrophils into the peripheral blood stream [90]. Functional aberrancy in 
these systems leads to impaired wound healing [91]. In a collaborative pathway, the release 
of chemoattractant factors by neutrophils, such as lactoferrin, attracts monocytes and 
activates macrophages [92]. A counterpart to recruitment is obviously needed to ensure 
robustness of a tissue, or else an overabundance of cells could lead to tissue destruction. 
Efferocytocis, transmigration, and specific apoptosis allow recruited cells to be cleaned up 
after damages. 
 
As the rest of the paper will show, two kinds of consequences follow from this analysis of the 
five key features of the TRS. First, it offers an important basis to re-think some tissue 
reconstruction-associated pathologies as dysfunctions of robustness. Second, it offers a test 
case to assess the usefulness of the notion of robustness in physiological and pathological 
conditions, and leads to distinguishing different forms of robustness.  
 
3. Dysfunctions of the tissue reconstruction system 
 
It has been suggested by Kitano and others that the concept of robustness can shed light on 
certain pathological processes [2]. Pathologies could result from robustness as a dysfunction 
(the process under consideration is robust, but this robustness is detrimental to the 
organism, as happens for example in AIDS or some cancers, where the robustness of a 
system is “hijacked” [2,93,94]) or a dysfunctional robustness, which is to say a rupture of 
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robustness (i.e., the process should be robust, but is not). This approach applies very well to 
the dysfunctions of the TRS.  
 Mechanisms that mediate tissue reconstruction to ensure robustness are constantly 
challenged. These mechanisms are sometimes overwhelmed, leading to various 
consequences depending on the situation, from the rupture of robustness to the promotion 
of the disease thanks to robustness-associated mechanisms, and to an excess of robustness. 
The final consequence of each situation is a pathological process. Through concrete 
examples (ulcers, fibrosis, and cancers), we will illustrate these different threats to the TRS 
to ensure robustness, emphasizing in each case exactly which mechanisms are challenged 
(see Table 1, which present several additional examples).  
 
3.1. Ulcers, or rupture of robustness 
 
Pathological situations of insufficient repair such as ulcers underlie that the TRS mechanisms 
ensuring robustness are overwhelmed. Since the robustness of the tissue can be 
jeopardized, it is important to analyze the various components listed earlier. The value of a 
more detailed analysis of component robustness is dual. This makes it possible to precisely 
identify vulnerabilities, which vary depending on the clinical situation, but also to work out 
innovative therapeutic strategies. As we saw, cell plasticity is a crucial dimension of the TRS 
and it is especially true for neutrophils. This is confirmed by the fact that incapacity of 
neutrophils to switch plastically from one state to the other can contribute to ulcers, e.g., 
skin or gastric ulcers. Impossibility of tuning the response toward a pro-resolving phase by 
experimentally blocking neutrophils in a pro-inflammatory state directly leads to chronic 
inflammation and deregulation of the TRS [95], while the reintroduction of very plastic cells 
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in damaged tissues can overcome this defect. Understanding that in this case the ulcer is a 
rupture of the robustness due to insufficient cellular plasticity allows to consider completely 
new therapeutic options. Several studies in animal models showed that adipose tissue-
derived stem cell sheet application to mucosal or skin wounds accelerates wound healing 
and decreases the degree of fibrosis [96,97].  
While inflammation has to be regulated to ensure the completion of the TRS, a 
failure in that process can lead to a rupture of robustness. A deficiency of efferocytosis has 
been identified as a causative agent of sterile chronic granulomatous disease in mice [98]. In 
chronic ulcers, favoring the resolving phase (e.g., through efferocytosis, pro-Treg 
therapeutics, or resolving compounds) could be an innovative strategy [99–101]. Even 
though defects of inflammatory regulation are clearly involved in the deregulation of the 
TRS, therapeutic avenues to counteract these defects are still in their infancy, and mostly 
limited to animal models. A better understanding of the crucial place of that mechanism in 
the global robustness of the TRS will tend to raise the interest for therapeutics targeting 
regulation. 
In ulcers, the loss of epithelial cells disturbs the ongoing surveillance of the TRS. In 
the eye, the inflammation of the cornea leads to damages of this protective barrier. Given 
that the cornea is an avascular tissue and contains few immune cells, corneal resident cells 
function as sentinel cells as well as immune modulators during corneal inflammation. They 
are able to sense bacterial infection through toll like receptor (TLR)-mediated detection. As a 
consequence, a loss of substance (i.e., a very significant injury) could lead to the 
disappearance of key first-line sentinel cells, normally responsible for the recruitment of 
other crucial cells in the repair process [102,103]. Other resident cells are involved in this 
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mechanism (see Table 1). Targeting sentinels could constitute a new therapeutic avenue in 
the treatment of chronic ulcers. 
Finally, due to the reduction of the dynamic flow to the damage site, new cells 
cannot come from the upstream and revitalize the system in an ulcer. Promoting the 
migration and proliferation of cells could accelerate wound healing [104,105]. 
Each of the five components of robustness can be compromised depending on the 
type of ulcer. For clinicians, thinking according to our classification and identifying which 
mechanism is deficient can therefore change very concretely their therapeutic management. 
 
 
3.2. Fibrosis or excess of robustness 
 
Keloid and hypertrophic scars can also be seen as the result of a dysfunction in the 
fundamental mechanisms of the TRS. One could consider fibrosis as a kind of hypertophic 
scar, and as such fibrosis could follow from a deregulated TRS as well. In a normal repair 
cycle, the resolution of damage-induced inflammation allows the system to rebuild itself 
efficiently. In contrast, the absence of resolution means the persistence of inflammation and 
also, especially in fibrosis, a disconnection between the levels of resolution and remodeling.  
An excess of plasticity can also be pathological. For example, epithelial-mesenchymal 
transition (EMT) reflects a high level of cell plasticity essential during embryogenesis and 
wound healing, but EMT can be aberrantly regulated in fibrosis [106,107]. Cell plasticity 
could also be a hurdle for achieving some cell therapy. A pro-fibrotic microenvironment 
results in systematic M2 polarization even if macrophages of another type are injected. In 
contrast, the infusion of stabilized pro-resolving macrophages is associated with reduced 
 19 
kidney interstitial fibrosis and inflammation, as well as preservation of the phenotype and 
functions of macrophages [108]. Thus, a precise knowledge of the proper physiopathology of 
the studied condition is crucial to understanding whether a higher or a lower plasticity is 
needed. 
The cause of fibrosis is sometimes attributed to the persistence of damage triggers 
such as chronic infection. Nevertheless, in hepatitis C, it is the inadequacy of the TRS 
response rather than the persistence of the infection that is at stake [109]. Tregs or pro-
resolving cells have also been suspected to be involved in more general fibrotic processes, 
such as systemic sclerosis (SSc) [110,111]. From this point of view, promoting the resolution 
of inflammation could be considered as a key aim to reverse fibrosis [112,113]. 
A constant monitoring is an essential element of the TRS responsiveness. The fact 
that it is provided by resident cells guarantees this prompt response when damages occur. 
However, in some cases, including fibrosis, this surveillance can be over-stimulated and 
associated with an overly sustained response. As described before, innate immune signaling 
via TLRs is a key driver of persistent fibrotic response. Chronic signaling on resident 
mesenchymal cells underlies the switch from a self-limited repair response to non-resolving 
pathological fibrosis characteristic of systemic sclerosis. Limiting the responsiveness of 
resident cells to innate stimulation could be of interest to prevent fibrotic processes [111]. 
Resident cells themselves can also be responsible for the excessive stimulation without any 
clear external trigger [114–116].  
A static TRS cannot result in normal repair. Indeed, different but more or less 
intricate phases must follow one another. Nonetheless, an excess of migration of pro-fibrotic 
cells into the tissue can be detrimental in a normal repair process. This happens, for 
example, in the lungs with fibrocytes. These cells enter the lungs in response to their 
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chemoattractant CXCL12, and differentiate into fibroblasts or myofibroblasts, leading to 
excessive deposition of collagen-rich extracellular matrix. It has been shown that inhibiting 
the flow of fibrocytes to the lungs by a peptide called R1R2 attenuates pulmonary fibrosis by 
reducing the invasion of fibrocytes through basement membrane-like proteins [117].  
 
3.3. Cancer or hijacking of robustness 
 
Cancerous tumors have been related to deregulated repair by Dvorak, who describes them 
as “wounds that do not heal” [118]. It is now well established that an inflammatory 
microenvironment promotes cancer [119]. It has also been suggested that the formation and 
maintenance of a cancerous tumor could be seen as a robust process [120]. Here we 
consider cancer as evolving from a damaged tissue, where the TRS could act to prevent the 
expansion of the injury and promote repair. The cancerous tumor, to drive its own 
development, hijacks some properties of the TRS that normally ensure robustness in 
physiological conditions. 
Epithelial-mesenchymal transition (EMT) is an important process in embryonic 
development, fibrosis, but also in cancer metastasis. The activation of EMT in cancer allows 
cells to acquire migratory, invasive, and stem-like properties. SCAI is characterized as a 
tumor suppressor inhibiting metastasis in different human cancer cells, and which is thought 
to be reduced in some tumors. SCAI expression decreases in a model of endothelial-
mesenchymal transition, which suggests that it could be important for cell plasticity. 
Nevertheless, its role in cancer remains to be further investigated, as its expression could be 
associated with high or low progression of the tumor depending on the type of cancer [107]. 
Macrophage polarization could influence immune checkpoint therapy resistance. The 
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plasticity of macrophages is used by cancerous tumors, and targeting this plasticity could be 
of interest to increase the response to immunotherapy such as ipilimumab [121].  
Redundancy may explain cancer resistance to certain treatments. Recently developed 
immunotherapies do not target the tumor cells as such; instead, they promote the local 
immune responses in the tumor microenvironment, which has some important 
consequences on key immunological actors of the TRS. Redundancy of the TRS becomes 
central in these conditions [122]. For example, IL-6 belongs to a family of cytokines with 
highly redundant functions, which use the glycoprotein 130 chain for signal transduction. It 
has an important role in the pathophysiology of multiple myeloma, where it supports the 
growth and survival of the malignant plasma cells in the bone marrow. Because of this 
redundancy, targeting IL-6 is highly difficult. Antibodies against glycoprotein 130 constitute a 
better option, as they can overcome this redundancy [123]. 
Insofar as cancer may be seen as both a cause and consequence of tissue damages, 
cancer cells could activate the TRS. In particular, cancerous tumors can use the above 
described restrain mechanisms of the TRS to induce a type of immune tolerance that will be 
at their own advantage. Tumor associated macrophages (TAMs) are one of the main actors 
of this phenomenon. Different therapeutic strategies have been proposed to address this 
problem, such as the suppression of TAM recruitment, their depletion, the switch of M2 
TAMs into antitumor M1 macrophages, and the inhibition of TAM-associated molecules 
[124]. 
Immune surveillance could be considered as insufficient in cancer. The TRS lets 
cancer cells grow and develop as if it were incapable of “seeing” them. Resident memory 
CD8+T cells (TRMs) represent a recently described subset of long-lived memory T cells that 
remain in the tissues, do not recirculate, and are therefore very important actors in 
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immunosurveillance. It has been shown that TRMs were present in human non-small cell 
lung tumor tissues, and their frequency was correlated with better overall survival than 
other infiltrating immune cells. In that case, the cancer misleads the immunosurveillance 
system, which suggests that strategies increasing the number of TRMs or activating them 
such as vaccines could be developed following this concept [125]. 
Prior to metastatic cell arrival, a premetastatic niche in distant organs could be an 
important step in the metastatic cascade. This phenomenon suggesting highly dynamic 
process from cancer cells could be preceded by neutrophil migration and recruitment. As 
such the dynamic property of the TRS is used to prepare the basis for tumor cell engraftment 
in parenchyma [126].  
 
Overall, the concept of robustness helps better understand TRS-associated 
pathologies, either as a deficiency in the fundamental processes by which robustness is 
normally realized (plasticity, etc.), or as an emerging, local form of robustness that is 
detrimental to the organism. 
 
 
4. Conclusion: the virtues of thinking about tissue reconstruction in terms of robustness 
 
In light of the various physiological and pathological examples examined in this paper, we 
propose that it is extremely fruitful to conceive of the tissue reconstruction system in terms 
of robustness, for three main reasons.  
 First, the recognition by Kitano and others [2] of different robustness-promoting 
mechanisms (system control, alternative mechanisms, modularity, decoupling) constitutes a 
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useful conceptual framework to better describe the TRS and its dysfunctions in pathological 
situations. For example, plasticity and redundancy of immune components within the TRS 
have been described by scientists who were supportive of the concept of robustness [47,58], 
and it seems likely that continuing to apply this concept will reveal even more plasticity and 
redundancy. Moreover, thinking in terms of robustness helps understanding that even a 
situation that could seem static, such as skin renewal for example, is in fact the outcome of a 
highly dynamic, continuously ongoing, process, and that it is pivotal to study in detail the 
mechanisms ensuring this process. It also suggests that the “default state” of the TRS is to be 
on alert, which means that tissue reconstruction is always active, though under constant 
restraint. As soon as the brake is lifted, the whole process of tissue repair (i.e., inflammation, 
tissue formation, and tissue remodeling) is triggered, which guarantees a higher capacity to 
react to various and often inevitable damages. Of course, this constant activation is 
energetically costly, but one should keep in mind that it is a low-level activation, and that it 
is probably essential for survival.  
 From a pathological point of view, the emphasis on the redundancy of the TRS, for 
example, is of the utmost importance. It shows that it is often entirely inadequate to hope 
for important benefits by intervening on just one actor or pathway. Indeed, in many cases, 
although some cells or pathways seemed crucial in a pathological process in vitro, their 
inhibition in vivo does not lead systematically to the pathological phenotype, because of the 
redundancy of some components and pathways. In other words, some pathological 
conditions reveal the role of certain cells or pathways, which are not normally indispensable, 
but become central when other components are missing. For example, alarmins IL-25, IL-33, 
and TSLP have a high level of redundancy, which makes anti-fibrotic treatments very difficult 
to develop. Blocking a single pathway is most often ineffective, so it is more promising to 
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consider modulation of the response at a very early stage, or to identify common pathways 
that could be targeted. Moreover, acting on one of the mechanisms of robustness while 
others play a more significant role is not effective in achieving repair. This is probably what 
happens when one treats fibrosis with immunosuppressive therapy in cases where restoring 
cellular plasticity would in fact be more adequate. As a general rule, then, one should never 
draw hasty conclusions about whether or not some actors have an important role in the TRS 
before having tested them in real-life pathological conditions. 
Second, the example of the TRS can, in turn, help us make some crucial conceptual 
distinctions about robustness. On the basis of the examples explored here, one can indeed 
distinguish functional vs. structural robustness, partial vs. complete robustness, and 
corrective vs. preventive robustness (Figure 2). Functional robustness in the case of the TRS 
means that tissue function (or, at least, one tissue function) is restored, but not tissue 
structure. For example, after significant skin injury, a scar will form, which will restore the 
protective function of the skin, but the initial structure of the skin will not be restored. In 
contrast, regeneration often leads to the restoration of both the structure and the function 
of the tissue. For example, adult zebrafish fins, including their complex skeleton, regenerate 
exactly to their original form within two weeks after an amputation. Importantly, some 
forms of complete tissue regeneration can also be observed in mammalian embryos, but this 
capacity is subsequently lost for most tissues (the most significant exception in humans is 
the liver, which can indeed regenerate, though it does not always recover its initial 
structure). Along similar lines, it is important to emphasize that robustness to a given 
challenge and at a certain level can be more or less effective. Robustness is partial when 
tissue function and/or structure is not completely restored, as illustrated by most cases of 
tissue repair in mammals, for example. Robustness is said to be complete when tissue 
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function and/or structure is entirely restored, as illustrated by cases such as fin regeneration 
in zebrafish already mentioned, limb regeneration in many amphibians [127], or tissue 
regeneration in many echinoderms [128]. Furthermore, robustness can be corrective or 
preventive. It is corrective when it consists in the active restoration of a strongly disturbed 
state. For example, tissue repair or regeneration after significant damages is a form of 
corrective robustness, because it follows a major perturbation (damages), and it involves, as 
we saw, a complex, dynamic, and regulated interplay of many different components. In 
contrast, robustness is preventive when it occurs in the absence of a major perturbation 
while minimizing the risk of a major perturbation and its detrimental consequence. For 
example, epithelial repair occurs continuously in the body, which requires an extremely rich 
orchestration of events [129]. This preventive robustness helps insure that the skin is always 
sufficiently “sealed off” and at the same time sufficiently smooth to achieve its functions. 
When this process is interrupted, for example in ulcers, the organism is at a high risk of 
being damaged and invaded by pathogens or toxic substances. Of course, there will be a 
grey zone here, because it is not always clear whether a perturbation is major or not, and 
different tissues are likely to perceive perturbations differently. For example, the liver is 
constantly exposed to toxic chemicals that could endanger the rest of the body, and its 
regenerative capacities are certainly evolutionarily related to this particular exposition [30]. 
Figure 2 sumps up the three distinctions proposed here (structural vs. functional; partial vs. 
complete; corrective vs. preventive. It is likely that these distinctions could be useful in other 
biological and engineering contexts, beyond the example of tissue repair and regeneration 
examined in the present paper. 
An additional distinction seems important to better grasp the role of robustness in 
pathological contexts. Dysfunctions in robustness of the TRS can indeed be understood along 
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two different lines. In some cases, the tissue fails to be robust, presumably because one or 
several important components or pathways of the TRS are not working properly. This is what 
we call a dysfunction of robustness. For example, we saw that the incapacity to realize cell 
plasticity can sometimes lead to the failure of tissue reconstruction. Yet, in other cases, the 
tissue is robust, but this robustness is, in this specific context, detrimental to the organism. 
This is what we call robustness as a dysfunction. For example, a tumor can constitute a 
robust tissue, which is well vascularized, nourished, and constantly repaired, often via the 
co-optation of classical physiological mechanisms to the benefit of the tumor itself. Here 
again, this distinction between a dysfunction of robustness and dysfunctional robustness 
might prove useful in other contexts, beyond the case of the TRS. 
A third and final consequence concerns the very understanding of immunity. Since 
the beginnings of immunology, immunity has been conceived primarily as a form of defense 
– most often against pathogens. Yet, if the perspective offered in this paper is correct, then 
immunity needs to be re-defined within a much wider context. Immune processes, we 
submit, concern not only defense, but also the construction (development) and 
reconstruction (constant repair; occasional repair after a significant damage; regeneration) 
of the organism,. Indeed, a typical immune system in nature is constantly busy surveying, 
renewing, and repairing the body,. This is not to say, obviously, that immune defense is not 
important, and has not been a major selective pressure in the evolution of immune systems. 
Our suggestion is that immune systems have evolved under a multidimensional complex 
selective pressure, which includes a capacity to develop and repair as well as a capacity to 
defend against different sorts of threats. The way scientists traditionally delineate the 
immune system reflects an intellectual decision. This does not mean, of course, that the 
immune system is not “real”, but rather that there exist many different ways to divide up 
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living entities into different “systems”. In the present paper, we have argued in favor of 
another intellectual decision by suggesting that it is more appropriate to focus on a 
functionally defined “system” of interest (namely the tissue reconstruction system) than on 
traditionally defined systems (such as the immune system). Repair and defense are probably 
just two sides of the same coin – a lesson that thinking immunity in terms of robustness 
might help us keep in mind. 
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Figures and Tables 
 
TRS 
robustness 
Dysfunctions in TRS robustness 
Ulcer 
(rupture of TRS robustness) 
Fibrosis 
(excess of TRS robustness) 
Cancer 
(hijacking of TRS robustness) 
Plasticity 
- Adipose tissue-derived stem 
cells accelerate wound 
healing [96,97] 
- N1 polarization by H. pylori 
in gastric ulcers [95] 
EMT and SCAI in renal fibrosis [107] 
- MET/EMT with the tumor-
initiating ability required for 
metastatic colonization [130] 
- Plasticity between the 
epithelial and the mesenchymal 
states rather than a fixed 
phenotype [131] 
- UPR in macrophage 
polarization and plasticity with 
shift to M1-like profile [121] 
Functional 
redundancy ILC redundancy [42] 
- IL-25, IL-33, and TSLP redundancy 
and fibrosis [132,133]  
- Targeting porcupine in kidney 
fibrosis and Wnt O-acylation [134] 
- IL-6 and glycoprotein 130 in 
the pathophysiology of multiple 
myeloma [123] 
Constant 
surveillance 
- Loss of substance (i.e., a 
very significant injury) and 
disappearance of sentinel 
cells in ulcers [103] 
- Langerhans cells and 
hypoxia [135] 
- Fibronectin-EDA and tenascin-C 
sensed by TLR4 on resident cells and 
fibrotic processes [111] 
- ILC2s in pulmonary fibrosis 
[114,115] 
- CD8+CD28- T cells and profibrotic 
cytokine IL-13 in the skin of systemic 
sclerosis (SSc) patients [116] 
- TRMs in human non-small cell 
lung tumor tissue [125] 
- Role of amphiregulin in 
orchestrating responses to 
tumors [136] 
 
Restraint 
- Resolution deficiency and 
sterile chronic granulomatous 
disease [98–101] 
- Imbalance Treg/Th17 in 
pyoderma gangrenosum 
[137] 
- Chronic hepatitis C and hepatic 
fibrosis with the Th17/Treg balance 
[109] 
- Role of TRegs in SSc [110] 
- SSc and TLRs with persistence of the 
response [111] 
- Resolving inflammation against 
fibrosis and specialized pro-resolving 
lipid mediators [112] 
- Macrophages and efferocytosis 
[113] 
 
- TAMs recruitment in triple 
negative breast cancer [124] 
- Tregs in tumor progression 
[138] 
- Tregs and cancer cell clearance 
[139]  
- Tregs and cancer 
immunotherapies with IL-2 [140] 
- To target immune checkpoints 
such as CTLA4, PD1 or TIGIT to 
both interfere with Treg 
function and enhance effector 
responses at the same time 
[141] 
Dynamic 
adjustment 
- Electrical stimulation and 
migration [105] 
- Selective migration and 
wound healing [104] 
Fibrocyte migration to the lungs 
inhibited by R1R2 attenuates 
pulmonary fibrosis [117] 
- Cancer cells and use of the 
dynamic potential of neutrophils 
[126] 
- CCL26 in colorectal cancer cells 
invasion by inducing TAM 
infiltration [142] 
- Inhibitors of the receptor 
tyrosine kinase c-MET and 
impairment of the mobilization 
and recruitment of neutrophils 
into tumors [143] 
 
Table 1. Main mechanisms involved in the robustness of the tissue reconstruction system (TRS), and its 
dysfunctions in major pathological situations (ulcer, fibrosis, and cancer). 
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Figure 1. Overview of the “tissue reconstruction system” (TRS). Many various components and pathways are 
involved in both tissue repair and tissue regeneration. Crucial components of the TRS include structural (e.g., 
fibroblasts, extracellular matrix, etc.) and immunological (e.g., neutrophils, macrophages, etc.) components. 
The concept of TRS is intended to embrace all the main entities and mechanisms responsible for tissue repair 
and tissue regeneration. 
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Figure 2. The exploration of the tissue reconstruction system (TRS) leads to distinguishing different types of 
robustness, namely structural vs. functional robustness, partial vs. complete robustness, and corrective vs. 
preventive robustness. The four cases presented here are merely illustrations, among others, showing how 
these distinctions can be applied to real-life cases. In severe skin injury, robustness is corrective, partial, and 
functional. In liver regeneration in mammals, robustness is corrective, almost complete, and functional. In the 
continuous renewal of epithelia, robustness is preventive, complete, and functional. Finally, in limb 
regeneration in salamander, robustness is corrective, complete, and functional. 
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